FRANKFURT, Jan 6 (Reuters) - A class of treatments known as antibody-drug conjugates (ADC) combine cancer-tracking proteins with powerful cell toxins. The therapies are getting a fresh start as dozens ...
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
Antibody drug conjugates (ADCs) combine specific antibody targeting of tumour cells with the potent cytotoxic effect of a chemotherapeutic agent. Despite their conception in the early 1900’s, there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback